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Summary
Data integration is the problem of combining multiple data groups (studies, cohorts) and/or
multiple data views (variables, features). This task is becoming increasingly important in many
disciplines due to the prevalence of large and heterogeneous data sets. Data integration commonly
aims to identify structure that is consistent across multiple cohorts and feature sets. While such
joint analyses can boost information from single data sets, it is also possible that a globally
restrictive integration of heterogeneous data may obscure signal of interest. Here, we therefore
propose a data adaptive integration method, allowing for structure in data to be shared across
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1
ar
X
iv
:1
91
1.
04
92
7v
1 
 [s
tat
.M
E]
  1
2 N
ov
 20
19
2 J. Kallus and others
X34
X13 X14
X23
p3
p1
p4p2
p1 p1 p1
p2 p2
p3 p2 p3 p3 p4
X13 X14X13X12X13
X23 X23 X24
D)C)B)A)
Fig. 1. Examples of A) multi-group, B) multi-view, C) multi-group and multi-view, and D) augmented
multi-view data. pi is the dimensionality of view i and Xij is the data matrix that contains data for views
i and j.
an a priori unknown subset of cohorts and views. The method, Multi-group Multi-view Principal
Component Analysis (MM-PCA), identifies partially shared, sparse low-rank components. This
also results in an integrative bi-clustering across cohorts and views. The strengths of MM-PCA
are illustrated on simulated data and on ’omics data from The Cancer Genome Atlas. MM-PCA
is available as an R-package.
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1. Introduction
Large-scale studies commonly involve multiple sources of data. These data sets can stem from
in-house experiments, public data-base resources, studies conducted in different experimental
settings or obtained through different technological platforms. There is thus an ever increasing
need to provide analysis methods that can integrate heterogeneous data from several cohorts or
studies and several sets of features.
The integration of data from multiple cohorts observed across a common set of features is
commonly referred to as multi-group integration (Figure 1A). Similarly, the multi-view (multi-
source, multi-modal) data integration problem focuses on one cohort where multiple sets of features
or measurements are available (Figure 1B). The multi-group and multi-view settings are to some
extent equivalent algorithmically. By transposing the data matrices of a multi-group data set, it
can be analyzed by multi-view methods and vice versa.
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Several methods for multi-view (or multi-group) integrative data analysis are based on PCA or
SVD. Here, we provide a brief summary while an extensive literature review can be found in the
online supplement (Table 2). Methods that extend to more than two matrices are generally limited
to finding a joint structure shared by all matrices. The interpretational value of multi-group (or
multi-view) data integration can be improved by also modeling properties that are only present in
one data matrix. van der Kloet and others (2016) present a comparative review of such methods,
including JIVE (Lock and others , 2013), DISCO-SCA (Schouteden and others , 2013) and O2-PLS
(Trygg, 2002), in the context of multi-view data. The three methods all fit a global model for the
joint structure and individual models to the residuals in each matrix. They differ primarily in how
strongly they impose assumptions of orthogonality of the individual structures of each matrix.
Recently, Feng and others (2018) proposed AJIVE which uses the same model as JIVE but with
improved computational efficiency for parameter estimation. Zhu and others (2018) developed
GIPCA: a generalization of JIVE to different data types which also allows for the presence of
missing values.
To enhance interpretability further still, sparsity constraints can be applied to the structure
parameterizations (e.g. the loadings of an SVD-based analysis). For example, Wang and others
(2015) proposed sMVMF to provide a decomposition of multi-group data into global and individual
signal while imposing sparsity penalties on the global and individual loadings. This results in a
stratification of features into sets that are; (i) globally relevant to explain all data groups; (ii)
individually relevant; and (iii) irrelevant.
Simultaneous data integration for multi-group and multi-view data (Figure 1C) was first
addressed by LÃűfstedt and others (2012). The method, bi-modal OnPLS, can decompose such
datasets into global and individual signal. Linked matrix factorization by O’Connell and Lock
(2017) later extended JIVE to the same generality, with the additional ability to handle elementwise
missing data. BIDIFAC (Park and Lock, 2019) is another extension of JIVE which, in addition,
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allows signal to be group-global and view-global.
In this paper, we aim to generalize the multi-group and multi-view integration to allow
information to be only partially shared across a subset of groups and/or a subset of views. In
many applications, a dataset may contain heterogenous matrices, and it is therefore unlikely that
a globally shared signal exists. In such datasets, methods that only look for globally joint signal
are forced to explain all variation as individual.
Argelaguet and others (2018) recently developed MOFA, which is, to our knowledge, the only
method for multi-view data that can find joint signal shared only for a subset of matrices. Klami
and others (2014) proposed CMF to perform multi-group and multi-view integration with loadings
that are shared by a subset of matrices. Both MOFA and CMF utilize a Bayesian setup, where an
automatic relevance determination (ARD) prior is used for each loading so that some are active
for only a subset of its associated data matrices. The ARD prior does not generate exact zeros.
Consequently, it is difficult to interpret results in terms of which data matrices have a common
structure, and how that common structure should be characterized. Furthermore, it does not
favor low rank models. CMF does not produce sparse loadings. MOFA combines an ARD prior
with a spike-and-slab prior where the role of the spike-and-slab prior is to produce sparse loadings
(feature selection) but this setup has not been generalized to a multi-group and multi-view setting.
We propose a frequentist multi-group and multi-view data integration method, MM-PCA, that
utilizes a symmetric treatment of views and groups, paired with regularization, to achieve; (i) partial
component sharing across subsets of groups and/or views; (ii) orthogonal components through an
efficient parametrization; (iii) sparse loadings and scores with respect to each component; and, (iv)
adaptive rank selection for the integrative procedure. Comparing MM-PCA to CMF, CMF offers
an approximate solution to (i) and does not provide solutions for (ii-iv) which greatly reduces the
interpretability of the CMF data integration procedure.
MM-PCA can be used for explorative analysis, for example integrative bi-clustering and
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the identification of key features that drive cohort stratification. In integrative genomics, such
driver-strata components can have relevance for development of new therapeutic solutions. To
demonstrate the strength and usefulness of MM-PCA we conduct simulations and apply MM-PCA
for the analysis of data from the Cancer Genome Atlas.
The rest of this article is organized as follows. Section 2 defines the model used in MM-PCA and
how its parameters are estimated and should be interpreted. In Section 3 we compare MM-PCA
with CMF, the only existing method of similar generality, and with JIVE, a popular method for
integrative analysis in genomics, in three simulation based experiments. In Section 4 we apply
MM-PCA to a data set from the Cancer Genome Atlas (TCGA, The Cancer Genome Atlas
Research Network and others (2013)). Section 5 concludes the article and discusses limitations
and potential future improvements.
2. Multi-group and Multi-view Principal Component Analysis
To facilitate the generalization of multi-group and multi-view integration, we treat the data
integration as symmetric with respect to group or view. Klami and others (2014) termed this
approach augmented multi-view data (AMD). To define AMD, let us consider nm data matrices.
Two matrices can be directly related by sharing rows or columns, or indirectly related via other
matrices. More precisely, two matrices share rows if row i in each of the two matrices concern the
same object, and similarly for columns. This defines a partition of the 2nm sets of rows/columns
into nv sets. We call such sets views, regardless of whether they consist of observations or features.
For example, consider two data cohorts; cohort 1 with p1 patients and cohort 2 with p2 patients.
Each cohort has two feature sets; the expression of p3 genes and the methylation state of p4 probes
(Figure 1C). There are 8 sets of rows/columns for 4 unique views. The generality of AMD allows
for the inclusion of a p3 × p4 matrix with prior knowledge of covariance between gene expression
and methylation. It also allows for inclusion of feature sets for which data are not available for all
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cohorts (Figure 1D).
Let Xij ((i, j) ∈ S) be a pi × pj data matrix, where S is the set of view pairs (i, j) for which a
data matrix exists. The cardinality |S| = nm is the number of matrices in the data set in total.
MM-PCA aims to find a rank k integrative solution to minimize the following loss
min
D·,V·
∑
(i,j)∈S
||Xij − ViDiDjV Tj ||2F , (2.1)
subject to V Ti Vi = Ik, i = 1, . . . , nv. Vi (pi × k) are the view-specific loading matrices and Di are
diagonal k × k matrices.
The optimal MM-PCA decomposition of a single data matrix X12 is V1D1D2V T2 , where
V1D1D2 is equal to the standard PCA scores for X12 and V2 is equal to the PCA loadings. Since
MM-PCA treats rows and columns symmetrically, we call all V· matrices loadings.
Without further constraints each column of Vi would influence all matrices Xi·. By imposing
exact zeros on some elements of the D· matrices we can constrain the MM-PCA components to
be shared between only a subset of data matrices. Since the D· matrices are diagonal and of the
same size, k × k, they can be compactly represented by a k × nv matrix D where each column is
equal to the diagonal of one of the D· matrices and each row corresponds to a MM-component.
We call D the augmented D matrix.
We now illustrate how a joint structure is defined by D . A zero at the element corresponding
to component c ∈ {1, . . . , k} (row) and view j (column) means that component c is not capturing
variation in data matrices with data for view j. Thus, all views with non-zero values for component
c contain variation that is jointly captured by component c. For example, consider matrices X12,
X13 and X14. If Dc,2 = 0 and Dc,j 6= 0, j = 1, 3, 4, then component c would be shared between
matrices X13 and X14 but not X12. If several rows of D have identical patterns of zeros, then the
corresponding components make up a subspace where the views with non-zero values co-vary.
D defines both the proportion of variation explained by estimated components and how much
of the explained variation that is shared between data matrices. Denote the optimal k-component
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MM-PCA solution for matrices Xij , (i, j) ∈ S byMk,nv = {Dk×nv , Vj , j = 1, . . . , nv}. The vector
DciDcj , c ∈ {1, . . . , k} is the vector of singular values of the approximation of Xij . Thus, the
proportion of variation explained by the k-rank solutionMk,nv of Xij is given by
R2(Xij | Mk,nv ) = ||ViDiDjV Tj ||2F /||Xij ||2F =
k∑
c=1
D2ciD
2
cj/||Xij ||2F .
Similarly, the proportion of variation in a matrix Xij that can be linearly predicted with another
matrix Xi′j′ can be computed as follows:
R2(Xij | Mk,nv , Xi′j′) =
∑
c∈C
D2ciD
2
cj/||Xij ||2F , C = {c : Dci′Dcj′ 6= 0},
where C is the set of components that influence Xi′j′ . This gives a directed relation between each
pair of data matrices, and can be used to form hypotheses of how groups of variables influence
each other (Figure 5B).
2.1 Estimation
We estimate the parameters V· and D· using quasi-Newton local optimization of the sum of the
objective (2.1) and four penalty functions (to be defined in Section 2.1.2).
Two problems arise ; (i) for relevant biological datasets the resulting optimization problem
involves a massive amount of parameters (order of 104 to 105); and (ii) the constraints are
challenging to handle numerically. Massive amount of parameters is not an insurmountable
problem in optimization, as seen for example in recent advances in the field of deep neural
networks. The constraints are challenging, however, in that they are non-linear and constrain the
set of feasible solutions to a manifold so that all solutions are on the border of the set.
To address these problems, we introduce a parsimonious parametrization for the loading
matrices. This not only reduces the number of parameters, but, more importantly, also removes
the optimization constraints.
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2.1.1 Parsimonious Parametrization Let V (e.g. V1) be k columns of a p-dimensional rotation
matrix, i.e. it is a matrix of pk parameters constrained to have orthogonal columns of unit `2-norm.
Such matrices are called k-frames and effectively have pk − k(k + 1)/2 free parameters (James,
1954).
To find a parsimonious parametrization of V we make use of a parametrization based on
Givens rotation matrices (Shepard and others, 2015). A rotation matrix for two-dimensional
rotation can be derived from angles, θ. Generalizing this definition to p-dimensional space requires
the multiplication of several rotation matrices, each constituting a two-dimensional rotation in a
two-dimensional subspace. Such matrices
Rij(θ) =

Ii−1 0 0 0 0
0 cos θ 0 − sin θ 0
0 0 Ij−i−1 0 0
0 sin θ 0 cos θ 0
0 0 0 0 Ip−j

are known as Givens rotation matrices.
We include in the supplement a proof in our notation that for p > k, an arbitrary p-dimensional
k-frame V can be expressed as a multiplication of m = pk − k(k + 1)/2 Givens rotation matrices
as V (ξ·) = (
∏p
i=1
∏k
j>iRij(ξ·,ij))Ipk, where Ipk are the first k columns of the p-dimensional
identity matrix. Each element ξ·,ij is an angle, and elements are collected in ξ·, a lower triangular
matrix with zero diagonal, of dimension p × k. The function V (·) thus yields a parsimonious
parametrization of k-frames from m angles.
This parametrization was recently used by Pourzanjani and others (2017) for Bayesian inference
of probabilistic PCA to facilitate sampling from a distribution over k-frames. It has not previously
been used for optimization based inference of SVD nor in the context of SVD based data integration,
and we have adapted the framework to more conveniently be applied for such tasks.
With this parametrization of k-frames we can restate (2.1) without the challenging orthogonality
constraints on the loadings. That is, we write for view i, Vi = V (ξi), ξi of sizes pi × k. When
computing V , the product of several large matrices, we make use of the sparse and regular
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structure of Givens rotation matrices.
We use the inverse of V (·), stated in the supplement, to find initial parameter values for the
optimization problem (2.1).
2.1.2 Loss, penalties and model selection We now restate the loss function as
∑
(i,j)∈S
||Xij − V (ξi)DiDjV (ξj)T ||2F +
4∑
c=1
λcPc(ξ,D),
with four added penalty terms to achieve; (i) data integration through the identification of partially
shared components; (ii) rank selection; (iii) sparse loadings; and (iv) variable selection.
Data integration is achieved via an `1 sparsity penalty on the diagonals of D·: P1(·, D) =
λ1
∑nv
i=1 ||Di||1, where nv is the number of views and || · ||1 is the sum of the absolute values of
the matrix’ elements. This penalty plays a similar role to the ARD prior on loadings used in CMF.
Unlike CMF, however, we have separated the loadings (V·) from their norms (D·). This allows us
to define an integration penalty that only involves a small fraction of the parameters.
The rank of solutions is penalized by adding a group penalty on each diagonal position across
all views: P2(·, D) = λ2
∑k
c=1
√∑nv
i=1(Di)
2
cc.
Sparsity of loadings is also achieved with an `1 penalty. To avoid solutions where less important
components tend to be more sparse, each V is multiplied by its associated D: P3(ξ,D) =
λ3n
−1
v
∑nv
i=1 ||V (ξi)Di||1.
Variable selection is achieved with a group penalty on each row of the loading matrices:
P4(ξ,D) = λ4n
−1
v
∑nv
i=1
∑pi
d=1 ||(V (ξi)Di)d·||2, where pi is the dimension of view i.
The division by nv is in both cases used to make all hyper parameters have approximately the
same scale.
To allow for missing elements in the data matrices, the corresponding terms of the loss function
are removed. For each data matrix Xij define a matrix Mij whose elements are zero if the same
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position in Xij is missing and one otherwise. The MM-PCA loss function thus becomes
∑
(i,j)∈S
||Mij 
(
Xij − V (ξi)DiDjV (ξj)T
) ||2F + λ1 nv∑
i=1
||Di||1+
+λ2
k∑
c=1
√√√√ nv∑
i=1
(Di)2cc +
λ3
nv
nv∑
i=1
||V (ξi)Di||1 + λ4
nv
nv∑
i=1
pi∑
d=1
||(V (ξi)Di)d·||2,
(2.2)
where S is the set of pairs (i, j) for which a data matrix Xij exists with rows concerning view i
and columns concerning view j and  is elementwise multiplication. This optimization problem
has nvk +
∑nv
i=1(pik − k(k + 1)/2) variables.
The D· matrices only enter the loss function in pairs, and thus DiDj , (i, j) ∈ S (Figure 6B)
are more directly informative than the D· themselves (Figure 6A). The former contain the joint
structure, the amount of variation explained and the amount of shared variation between matrices
(as defined above). Still, values in D· are not arbitrary. The penalty terms promote solutions
where the elements of the diagonal matrices are of similar size, and each D· may partake in several
matrices.
Optimization of the objective function (2.2) is performed with the Broyden-Fletcher-Goldfarb-
Shanno (BFGS) algorithm, a quasi-Newton method that makes use of the gradients of the objective
function (gradients shown in the supplement) for iteratively updating an estimate of the Hessian.
Details on how the various penalties are scaled to remove their dependencies on scale and size of
the data matrices are given in the supplement.
Values for the penalty parameters λ = (λ1, . . . , λ4) are chosen by dividing the elements of the
data matrices into a test set and a training set. Non-missing elements of the data matrices are
randomly assigned to the test set (with probability 0.1). For given values of λ, the model is fitted
with the elements of the test set treated as missing data. A λ is sought that minimizes the squared
reconstruction error of elements in the test set. The user can specify any sequence of candidate λ
values. To limit the search space we typically choose candidate values by deciding which penalties
that should be active (specified as four binary parameters (b1, . . . , b4)) and choosing a range and
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step size of values λ0. The set of candidate values is then given by λ = (λ0b1, . . . , λ0b4) for each
value of λ0. After the optimal λ has been found, the model is finally estimated using all data
(including the test set). Each candidate value of λ can be tried in parallel, making it possible to
utilize many processor cores simultaneously for parameter tuning.
2.1.3 Normalization and Initialization It is advisable to center both rows and columns of each
X similarly to normalization for ordinary PCA. One may also normalize data matrices in relation
to each other through scaling e.g. to equal Frobenius norm, (square) Frobenius norm proportional
to the number of elements, rows or columns, or equal Frobenius norm of the first principal
components. Further matrix-wise normalizations are discussed in Section 2.5 of LÃűfstedt and
others (2012). In the end, data normalization must depend on data or domain knowledge.
We initialize the optimization with an approximation of the solution under the assumptions
that all components are globally joint. Alternatively, MM-PCA can use CMF to find initial values.
The R package allows for both.
2.2 Components of the MM-PCA solution
To summarize the above sections, MM-PCA provides a multi-group and multi-view structure
decomposition of data matrices that includes;
(i) Automatic rank selection. MM-PCA estimates the optimal rank by using a group
penalty on the rows of D . The estimated rank is given by the number of rows in D that
contain non-zero elements.
(ii) Interpretable sparse loadings. Sparsity in loadings, that is in columns of V·, increases
interpretability.
(iii) Multi-group multi-view bi-clustering. Sparse loadings facilitate a direct translation
from the MM-PCA decomposition to an integrative bi-clustering of the data. Each column
12 J. Kallus and others
of the loading matrix partitions the observations or variables of a view into three groups:
positive, zero and negative. The use of sparse loadings for bi-clustering of a single data
matrix was explored in Lee and others (2010) which, with MM-PCA, is thus generalized to
the multi-group and multi-view setting.
(iv) Detection of outliers and irrelevant variables. Removing outliers (row or columns)
from the model is achieved via a group penalty on rows of V·. This penalizes difference in
sparsity structure between loadings for the same view. Removing an outlier means that the
corresponding row or column is considered to contain noise only.
(v) Imputation of missing values and missing matrices of data. Data matrix approx-
imations given by the fitted model have no missing values, thus achieving imputation.
Furthermore, data matrices that are not present when fitting the model, but that has views
that are present through other matrices, can be predicted. E.g. if Xij′ , Xi′j and Xi′j′ are
present, a missing matrix consisting of views i and j is predicted by Xˆij = ViDiDjV Tj .
3. Method Evaluation on Simulated Data
We investigate MM-PCA performance via three simulation studies. Simulation 1 is aimed at
demonstrating MM-PCA’s ability, compared with CMF, to correctly identify partially shared
structure in a data set. Simulation 2 investigates MM-PCA’s automatic rank selection and ability
to identify globally joint signal, where we compare against CMF and JIVE. Finally, simulation 3
demonstrates MM-PCA’s ability to identify sparse loadings.
3.1 Simulation 1
We generate four data matrices of size 10× 10, thought to represent four different cohorts (views
1 through 4) observed over a common set of features (view 5). Each matrix is the sum of a rank
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one matrix (the signal) and noise. Data matrices one and two share a rank 1 component, and
similarly for matrices three and four. That is,
Xi = uiv
T
i + cεi, i = 1, . . . , 4, u
T
i ∼ N(0, I)
vi = v˜i/|v˜i|2, v˜T1 = v˜T2 ∼ N(0, I), v˜T3 = v˜T4 ∼ N(0, I)
(3.3)
where each element of each εi is independent standard normal and c is chosen to obtain a fixed
signal-to-noise ratio (SNR).
Both MM-PCA and CMF are run with default settings. The correct noiseless data rank (two)
is given as input to both methods. This gives an advantage to CMF since it does not penalize the
rank of the estimated model.
We compare the estimated joint structure to the correct structure. Recall from Section 2, the
structure of the decomposition is captured by the augmented D-matrix, D . For row (component)
k of D , the non-zero elements describe which views share this component. Here, the correct
structure is that row k of D is non-zero for only columns (views) (1, 2) or (3, 4). As a metric
of structural error, we thus compute the RMSE distance between the MM-PCA D-solution and
the correct D . For CMF the estimated D is directly given by the `2 norm of the columns of its
loading matrix solution (see supplement). We also evaluate the reconstruction error with regard
to the signal term of each matrix.
Results, presented in Figure 2, are based on 100 simulation runs. MM-PCA outperforms CMF
in finding the correct joint structure (lower panel in Figure 2). CMF results do not provide explicit
zeroes which makes it difficult for the user to select a threshold to decide if a signal is shared
between matrices. Here, a range of threshold values were applied and the best results are reported.
By contrast, when SNR is moderate to high, MM-PCA often finds the correct structure exactly.
In terms of reconstruction error (upper panel), CMF performs better than MM-PCA due to
MM-PCA adhering to the more constrained (and correct) structure and due to penalization bias.
Including a debiasing step in MM-PCA has been left for future work.
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Fig. 2. Simulation 1 compares MM-PCA and CMF in terms of estimating the joint structure of four
matrices. The upper panel shows reconstruction loss and the lower panel shows error in joint structure.
MM-PCA outperforms CMF in terms of finding the correct joint structure but has a higher reconstruction
loss due to adhering to the more constrained (and correct) joint structure and due to penalization bias.
RMSE, root mean square error. SNR, signal-to-noise ratio.
3.2 Simulation 2
We generate three data matrices of size n × p, representing three cohorts (views 1, 2 and 3)
observed over a common set of features (view 4). Each observation is associated with either a
loading that is common to all three matrices (i.e. globally joint) or with a loading that is unique
for the matrix of that observation. We vary the proportion of observations that are associated
with the globally joint loading. Thus, in each matrix, each row lies either along the globally joint
direction or along the individual direction of the matrix. The individual directions v1, v2, v3 are
not orthogonal, they have pairwise angle of pi/3. Data is generated according to:
Xi = [viu
T
i v4w
T
i ]
T + εi, i = 1, . . . , 3
uTi ∼ N(0, I[p(1−pJ )]), wTi ∼ N(0, I[ppJ ])
v4 = v˜4/|v˜4|2, v˜T4 ∼ N(0, In)
(3.4)
where pJ is the proportion of data coming from the joint loading and where each element of each
εi is independent normal with mean zero and standard deviation 0.05. We generate data in two
settings; (n, p) = (100, 25) a low-dimensional case, and (n, p) = (10, 40) a high-dimensional case
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(with respect to the direction of integration).
MM-PCA is run with maximum rank 10 (the correct rank for this problem is four). CMF
is run with both rank four and rank 10. Since results were slightly, but significantly, better for
CMF with rank 10 these are reported. For CMF we find the approximate rank of the solution by
thresholding D . As in Simulation 1, a range of threshold values were tried and the best results
are reported. JIVE is run with its permutation testing method for rank selection. JIVE has an
option to assume that the individual loadings are orthogonal. This assumption makes JIVE more
robust to noise, though it is incorrect for this data. JIVE is run in both settings for comparison.
We evaluate the performance of the methods based on the estimated joint direction of the data.
If a method selects a model that does not estimate the existence of any globally joint direction,
the dominating direction of the residual is used as estimate of the joint direction. This is what a
sensible user would do if the goal is to find the globally joint direction rather than to decide if
such a signal exists. We choose to focus on this measure in order to facilitate a comparison of
methods of different complexity. Accuracy is defined as the estimated joint direction having a
smaller angular distance to the correct joint direction than to each individual direction and to the
dominating direction of the noise.
Results from 100 simulation runs are shown in Figure 3, the low dimensional case in Figures
3(A,C,E) and the high dimensional case in Figures 3(B,D,F). In the low dimensional case, CMF
finds the globally joint loading more often than MM-PCA (Figure 3A). In the high dimensional
case, MM-PCA is better (Figure 3B). JIVE without orthogonal constraint is the best performing
method for low joint proportion, but the method performs poorly and unpredictably for higher
joint proportions. This makes the method difficult to use in practice where the strength of the
joint signal is unknown. As the individual signals weaken (due to the joint proportion increasing)
JIVE tends to fail to separate the individual signals and misclassify them as joint. JIVE only
looks for globally joint signal (here correct) which gives JIVE a smaller search space compared
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to both MM-PCA and CMF. JIVE with orthogonal constraint shows a robust performance, but
the performance is poor compared to MM-PCA and CMF. MM-PCA shows the most robust
performance overall.
Figures 3C-D examine the methods’ estimates of the rank of the globally joint signal. The
correct rank is one except when the joint proportion is zero where the correct rank is zero. In the
low dimensional case CMF performs best while MM-PCA performs best in the high dimensional
case where CMF greatly overestimates. JIVE overestimates when the joint and individual signal
have near the same magnitude (joint proportion 0.5). Figures 3E-F examine the estimated rank of
each matrix. The correct rank is two, the globally joint component and the individual component,
except when the joint proportion is zero or one where the correct rank is one. Results show that
the rank selection of MM-PCA works as intended in this setting and that the performance of
MM-PCA is better than JIVE, despite MM-PCA addressing a much wider range of integrative
analysis settings. CMF again performs well in the low dimensional case but overestimates in the
high dimensional case. MM-PCA performs well in both settings, albeit being conservative.
3.3 Simulation 3
Simulation 3 demonstrates the ability of MM-PCA to estimate sparse loadings. We generate a
matrix of size 30×30. The matrix consists of two components and Gaussian noise. Each component
is the product of two sparse loadings with ones at three random positions and zeros elsewhere.
We compare the estimated components to true sparse loadings. MM-PCA is run with a
maximum rank of two whereas CMF is given the correct rank (two). As in the other simulations,
a range of threholds are applied to the CMF loadings to provide a comparison with MM-PCA.
Accuracy is measured with Matthews correlation coefficient (MCC).
Results from 100 simulation runs are shown in Figure 4 (upper panel). MM-PCA is able
to identify the sparse loadings with high accuracy for moderate to high SNR values. MM-PCA
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Fig. 3. Comparison of MM-PCA, CMF and JIVE in a low dimensional case (A, C and E) and a high
dimensional case (B, D and F). MM-PCA shows the most robust performance overall. In the low
dimensional case CMF performs well, but it falls short in the high dimensional case. JIVE performs
well only when the joint proportion is low. JIVE-OC (orthogonal constraint) performs robustly but
poorly. A and B) Accuracy at finding the globally joint component. Ordinary PCA (performed on the
concatenation of the three data matrices) is included as a baseline. C and D) Estimated number of globally
joint components. E and F) Estimated rank of each matrix. Dashed lines show the correct number of
components.
outperforms CMF in the entire SNR range, though this comparison is less meaningful than for
Simulations 1 and 2 since CMF has not been developed to explicitly provide sparse loadings.
We also investigate how MM-PCA rank-selection works in a sparse setting. Here, both MM-
PCA and CMF, included for comparison, are run with maximum rank 3. In Figure 4 (lower panel),
we see that MM-PCA performs quite well for moderate to high SNRs. In a few cases, MM-PCA
results in rank zero solutions due to poor initialization and those results are excluded from the
analysis. In this setting, thresholding the CMF solutions does not result in a rank selection. This
tendency for CMF to overfit was also seen in Simulation 2.
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Fig. 4. MM-PCA more accurately identifies the non-zero positions of the loadings and more often identifies
the correct rank. MCC, Matthews correlation coefficient. Dashed lines show the correct rank. SNR,
signal-to-noise ratio.
4. Integrative Analysis of Gene Expression and Methylation Data for Three
Patient Cohorts
We apply MM-PCA to a well established set of glioblastoma (GBM) data from TCGA (The
Cancer Genome Atlas Research Network and others, 2013). Earlier versions of TCGA data were
used to identify four subtypes of GBM, termed proneural (PN), classical (CL), neural (NL) and
mesenchymal (MS), by clustering of gene expression array profiles (Verhaak and others, 2010).
Analysis of methylation data from TCGA subsequently identified a subset of patients within
the PN subtype with favorable prognosis termed the G-CIMP (glioma-CpG island methylator
phenotype) subgroup, more frequently observed among younger patients (Noushmehr and others,
2010). Recent work has questioned the existence of the NL subtype, showing that a clustering
using only tumor-intrinsic gene expression identifies three subtypes (Wang and others, 2017).
Here, we analyze gene expression and methylation data centered around four canonical pathways
of GBM; mTOR, Ras, MAPK and PI3K-Akt, focusing on processes critical for glioblastoma
development and progression.
The data set consists of six data matrices: gene expressions for patient cohorts 1 and 2,
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methylation data for patient cohorts 2 and 3, and patient covariance matrices between cohorts 1
and 2 and between cohorts 2 and 3. This results in five views: the three patient cohorts constitute
three groups of observations, and the genes and methylation probe sites constitute two groups of
variables. Data preprocessing and normalization steps are described in detail in the supplement.
After filtering on high variance genes and methylation sites, the data set to be modelled comprises
three patient cohorts of sizes 96, 76 and 212, 297 genes and 305 DNA sites (Figure 5A).
4.1 MM-PCA Integrates Across Views and Cohorts
MM-PCA was applied with ten regularization levels, λ0 between e−8 and 1 on a logarithmic
scale. The lowest cross-validation error was found for λ0 ≈ 0.012. We allowed the solution
to have a maximal rank of 40. The selected solution has an effective rank of 24. Figure 5A
shows the data as modeled by the MM-PCA solution. The six data matrix estimates shown
are Xˆij = V (ξi)DiDjV (ξj)T , (i, j) ∈ {(1, 4), (2, 4), (2, 5), (3, 5), (1, 2), (2, 3)}. View indices 1, . . . , 5
label the five views in the order: cohort 1, cohort 2, cohort 3, genes, and methylation probes.
In Figure 5A matrix columns and rows are ordered according to the bi-clustering given by
the MM-PCA solution. The hierarchical nature of this clustering is shown with cluster trees for
each view. The importance of each component for each view is shown in Figure 6C. It is apparent
in Figure 5A that clusters are pronounced in all matrices associated with each view, i.e. the
clustering is integrative. One cluster is particularly pronounced. It can be seen as a bright yellow
wide rectangular area in the lower right part of the cohort 3 methylation data. We found that the
associated cluster of patients is strongly associated with low age and G-CIMP status (Section
4.2). MM-PCA thus detects the known connection between low age at diagnosis and G-CIMP
status in an unsupervised fashion. Looking at the methylation data for cohort 2 and covariance
between cohorts 2 and 3, it can also be seen that this patient cluster in cohort 3 is associated
with a patient cluster in cohort 2 with strongly correlated methylation. The cluster in cohort 2 is
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small and its presence is thus boosted through the integration with the larger cohort 3.
The partially shared structure, captured by D and R2 (defined in Section 2), is shown in
Figures 6A-D. Figure 6A shows the proportion of total variation of each matrix captured by each
component. Figure 6B groups components according to which views. Thus the set of components
with a given color in Figure 6B constitutes a subspace for variation in a subset of data matrices.
Figure 6C shows D of the MM-PCA solution. Figure 6D shows the proportion of variation
explained by each component, resulting in a scree-plot as commonly used in ordinary PCA.
Directed R2 is shown in Figures 5B-C. Methylation data explains variation in gene expression, in
agreement with their biological cause-effect relationship.
Figure 6C provides the basis for interpreting the components illustrated in Figure 5D-F.
Components 1, 2, 5 and 11 (Figure 5D) capture structure that is shared globally. Components 3,
7 and 8 (Figure 5E) capture structure that is primarily shared by cohorts 1 and 2 through gene
expression, but also models variation in methylation data for cohort 2. Components 4, 6, 9 and 10
(Figure 5F) capture structure that is primarily shared by cohort 2 and 3 through methylation,
but also additional variation in gene expression for cohort 2. The contribution of the remaining
components is small, mainly capturing variation in methylation in cohort 3
As with ordinary PCA, MM-PCA can be used to plot data in lower dimensions. In Figure 7B
we plot all observations by their first two loadings. Patients of different subtype and G-CIMP
status are separated already in the first two components. Ordinary PCA would not be able to
use the entire data set, but would need to base the analysis on either cohorts 1 and 2 and gene
expression or cohorts 2 and 3 and methylation data. From the MM-PCA plot one can infer a
plausible subtype and G-CIMP status for the observations with unknown status.
The MM-PCA solution can also be used for integrative bi-clustering of all observations and
variables (Figure 7A). This is in contrast to the bi-clustering in Figure 5A which clustered the
items of each view. We impute the two missing data matrices X˜15 (cohort 1 methylation data)
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and X˜34 (cohort 3 gene expressions) by multiplying the corresponding V· and D· matrices and
construct the bigger matrix
Xˆ =
Xˆ14 X˜15Xˆ24 Xˆ25
X˜34 Xˆ35
 =
V (ξ1)D1V (ξ2)D2
V (ξ3)D3
[V (ξ4)D4
V (ξ5)D5
]T
.
Similarly to the bi-clustering described above, we reorder columns and rows of Xˆ according to signs
of elements in [V (ξ1)T V (ξ2)T V (ξ3)T ]T and [V (ξ4)T V (ξ5)T ]T (positive, zero or negative). Cluster
hierarchies are shown as trees. We cut the trees at two heights, using two and three components,
resulting in 32 and 33 clusters, respectively. The low age, G-CIMP bi-cluster considered above
is again present, but now includes patients from all cohorts and some genes in addition to its
methylation sites (dark blue patient cluster, dark green variable cluster). A closer look at the
relation between cluster and subtype shows that CL is predominant in the red rank 2 cluster, PN
in the blue and MS in the green and purple clusters (Figure 7C). The split of the rank 2 purple
cluster into rank 3 light and dark purple clusters separates PN patients by G-CIMP status. The
analysis captures several clinical variables (Section 4.2), and the clustering is thus not primarily
focused on separation by subtype. GBM disease subtype has been shown to have little clinical
relevance (Johansson, 2018).
4.2 Leading MM-PCA Components Capture Subtype, G-CIMP and Clinical Features of GBM
To elucidate the potential biological and clinical relevance of the MM-PCA components we quantify
for each: the proportion of variation in each matrix and view explained by each component (Figure
6A-C), the proportion of total variance explained by each component (Figure 6D), the relationship
between each component and clinical parameters subtype, G-CIMP status, sex, age, survival
time, tissue type, stemness and pathway enrichment (Figure 6E-F, Table 1, Figures 8-13). P-
values are calculated using standard methods: Kruskal-Wallis test for factor variables, Fisher
z-transformation for continuous variables and Cox proportional hazard model for survival times.
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Fig. 5. A) Heatmaps showing MM-PCA approximations of the glioblastoma data. Dendrograms show
hierarchical integrative bi-clustering of patients and variables within each view. B) and C) Directed R2
depicted as a graph (B) and as a matrix (C). B) A directed connection is drawn for each directed R2
value above 0.35. The width of edges is proportional to the directed R2 value. C) Heatmap showing all
directed R2 values. D) Heatmap of only globally joint components. Signal captured by these components
is present in all data matrices. E) Heatmap of components shared by cohorts 1 and 2. F) Heatmap of
components shared by cohorts 2 and 3. Colors in headings D-F refer to Figure 6B. Heatmap colors in A)
and D-F): yellow: positive, turquoise: zero, blue: negative.
Tissue type indicates whether a sample is from a primary tumor, recurrent tumor or from normal
tissue. We use a machine learning based measure of stemness to quantify each sample’s degree
of oncogenic dedifferentiation (Malta and others, 2018). Pathway enrichment is assessed using
gene set enrichment analysis (GSEA, Subramanian and others, 2005) using v3.0 of javaGSEA
obtained from the Broad institute. Hallmark pathway annotations where obtained from MSigDB
v6.2 (Liberzon and others, 2015).
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Several components found with MM-PCA correlate significantly with clinical parameters
(Figures 8-13). Component 1 separates patients with MS subtype from patients with PN subtype.
The component is also associated with genes defining the epithelial-mesenchymal transition, a
hallmark pathway consistent with the gradient between the PN and MS subtype. Component 2
strongly separates G-CIMP patients from non G-CIMP patients as well as patients with CL subtype
from other patients. Component 3 captures variation in the expression data that associates with
several hallmark pathways including oxidative phosphorylation and mitotic spindle. The component
is associated with tissue type and correlates with the stemness signature. Component 4 captures
variation in the methylation data and is associated with subtype and G-CIMP status. Interestingly,
the component associates some CL subtype patients with G-CIMP patients, suggesting a set of
genes and probes where these CL patients are similar to G-CIMP patients. Component 5 captures
variation in both data types and describes variation between normal and tumorous samples.
Of note, a number of NL samples have high loadings for this component, possibly indicating
contamination of normal cells, which has been suggested as the basis for the NL subtype (Wang
and others, 2017). Component 6 captures patient sex, primarily by a small number of methylation
probes on chromosome X (e.g. IRAK1 and FLNA).
5. Discussion
We present a method for multi-group and multi-view data integration, MM-PCA, capable of
identifying partially shared components between any subset of data matrices. The goal of MM-PCA
is to provide a general data integration pipeline that is applicable to heterogeneous data where
global integration would be too restrictive.
MM-PCA provides a sparse, low-rank representation of multiple data matrices. The MM-PCA
solution is easily interpreted since; (i) each component is identified as associated with a subset
of data matrices; (ii) sparse component loadings directly translates the MM-PCA solution to
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Table 1. Significance tests for association of MM-PCA component loadings with clinical parameters,
stemness and gene signatures of hallmark pathways relevant to glioblastoma. Legend: ∗∗∗: p < 0.001,
∗∗: p < 0.01, ∗: p < 0.05, · : p < 0.1., Survival is not significantly associated, at the 0.05 level, with any
component after correction for age or sex.
MM-PCA component
1 2 3 4 5 6
Clinical: Subtype ∗∗∗ ∗∗∗ ∗ ∗∗∗ ∗∗∗
G-CIMP ∗∗∗ ∗∗∗ · ∗∗∗
Sex · ∗∗∗
Age ∗∗∗
Survival ∗∗ ∗∗∗ ∗∗∗
Cohort ∗∗ ∗∗ ∗∗∗ ∗∗
Tissue type · ∗∗∗ ∗∗∗
Stemness: mRNA ∗∗∗ ∗ ∗∗
Methylation ∗∗∗
Hallmark pathways: Epith. mesench. trans. ∗∗
Oxidative phosph. ∗
Mitotic spindle ∗∗
KRAS signaling DN ∗
an integrative bi-clustering procedure; and (iii) MM-PCA automatically selects the rank of the
approximation as part of the procedure.
We show through simulations that MM-PCA performs well in a range of settings including
low- and high-dimensional tasks, small and large proportion of joint variation, and low to high
signal-to-noise ratio. MM-PCA exhibits a robust and stable performance across this range, whereas
competitors CMF and JIVE perform poorly in some of these settings. This provides support
for using MM-PCA in real data settings where the underlying structure is unknown. We apply
MM-PCA to an ’omic data set of glioblastoma to illustrate the power of the method as an
explorative tool for complex data integration.
MM-PCA constitutes a complex optimization task. The current implementation takes 20
minutes to analyze the data treated in Section 4 on a 4 core 3.5 GHz desktop computer. On
simulated data, runtimes are on par with CMF (time per iteration is somewhat lower for MM-PCA)
despite MM-PCA adressing a more complex problem. Future work could be directed at providing
approximate solutions or optimization strategies to improve runtimes.
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To further extend the applicability of MM-PCA, the method should be generalized to other
loss functions (e.g. for binary data) and tensor data. This is left for future work.
6. Software
MM-PCA is available as an R package on CRAN.
7. Supplementary Material
Supplementary material is available in the appendix.
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APPENDIX
A. Literature Review
This literature review is summarized in Table 2 and the different data integration problems are
illustrated in Figure 1. The simplest case is the integration of data from multiple cohorts observed
across a common set of features, commonly referred to as multi-group integration (Figure 1A).
An early extension of PCA for multi-group data is CPCA (Flury, 1984). It summarizes a data
set consisting of several cohorts with one matrix of loadings that is common for all cohorts. The
multi-view (multi-source, multi-modal) data integration problem focuses instead on one cohort
where multiple sets of features or measurements are available (Figure 1B). The popular iCluster
algorithm (Shen and others, 2009) is an example of multi-view integration for genomic data.
Below we review methods for multi-group or multi-view data integration together since they are
algorithmically similar.
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Several classical methods for multi-view (or multi-group) integrative data analysis are based
on PCA or SVD. Canonical correlation analysis (CCA) (Hotelling, 1936) and partial least squares
(PLS) (Wold, 1974) are perhaps the most used and studied. They can only be applied to data sets
comprising two matrices, and they focus only on finding joint structure or parameters to explain
both matrices together. Hierarchical PCA, hierarchical PLS (Wold and others, 1996), generalized
SVD (Loan, 1976) and higher order generalized SVD (Ponnapalli and others , 2011) are extensions
to more than two data matrices but still limited to finding a joint structure shared by all matrices
in a dataset.
JIVE (Lock and others, 2013), DISCO-SCA (Schouteden and others, 2013) and O2-PLS
(Trygg, 2002) are methods that models data as a sum of both globally joint signal and signal that
is individual to each matrix. They estimate model parameters by iteratively alternating between
fitting a global model for the joint structure and fitting individual models to the residuals in each
matrix. O2-PLS applies only to datasets of two matrices but OnPLS (LÃűfstedt and Trygg, 2011)
generalizes it to an arbitrary matrix count. AJIVE (Feng and others, 2018) uses the same model
as JIVE but bases rank estimation on random matrix theory instead of bootstrapping. GIPCA
(Zhu and others, 2018) generalizes JIVE to allow for different data types and also allows for the
presence of missing values.
The method sMVMF (Wang and others, 2015) provides a decomposition of multi-group data
into global and individual signal while imposing sparsity penalties on the global and individual
loadings.
Simultaneous data integration for multi-group and multi-view data (Figure 1C) was first
addressed by bi-modal OnPLS (LÃűfstedt and others , 2012), an extension of OnPLS. The method
can decompose such datasets into global and individual signal. Linked matrix factorization
(O’Connell and Lock, 2017) later extended JIVE to the same generality, with the additional
ability to handle elementwise missing data. BIDIFAC (Park and Lock, 2019) allow signal to be
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group-global and view global, in addition to the global and individual signal. Integrative analysis
of data that is both multi-view and multi-group will become increasingly relevant in molecular
biology (Richardson and others, 2016).
MOFA (Argelaguet and others, 2018) is the only method for multi-view data that can find
joint signal shared only for a subset of matrices. Like sMVMF, MOFA also performs feature
selection. It does so by using a sparsity inducing prior.
CMF (Klami and others, 2014) builds on the augmented multi-view data (AMD, Figure 1D)
framework to perform multi-group and multi-view integration with loadings that are shared by
a subset of matrices. The partial sharing problem for multi-view integration was, as mentioned
above, addressed in MOFA. Both of these methods utilize a Bayesian setup. CMF uses the model
Xij = UiU
T
j + εij where each U and ε follow a Gaussian distribution. The model parameters are
estimated using variational Bayesian inference.
B. Generalized Euler Parametrization
We present the following corollary to the results of (Hoffman and others, 1972). It states that
k-frames can be factorized into pk − k(k + 1)/2 Givens rotation matrices.
Corollary 1. For p > k, an arbitrary p-dimensional k-frame V can be expressed asR1R2 · · ·RmIpk,
where m = pk − k(k + 1)/2, Ri are generalized Euler rotations and Ipk are the first k columns of
Ip.
Proof. Let V be an arbitrary k-frame and let W be any rotation such that V = WIpk. Such W
exist by the definition of k-frames. Hoffman and others (1972) gives W =
∏
16i<j6pRij which
can be factorized into (
∏
(i,j)∈ARij)(
∏
(i,j)∈AC Rij) where A = {(i, j) : 1 6 i < j 6 p ∧ i 6 k}
and AC = {(i, j) : k < i < j 6 p} since the factors of W are ordered so that this can be done
without reordering them. Furthermore (
∏
(i,j)∈AC Rij)Ipk = Ipk since all indices in AC are greater
than k. Thus V = (
∏
(i,j)∈ARij)Ipk. Lastly |A| = m. 
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B.1 Inverse
In order to find a good initial value for the optimization problem we need to find the angles that
correspond to a given k-frame V ∗, i.e. ξ = V −1(V ∗). Hoffman and others (1972) states this inverse
for rotations. To utilize the k-frames setup for MM-PCA, we here generalize the rotation inverse
to k-frames in the following way. Let U−1(U) be the inverse for rotations given in (Hoffman and
others , 1972), i.e. the function that gives the angles that correspond to a given rotation matrix U .
Using the orthogonal complement V ⊥ of V ∗ and that [V ∗ V ⊥] is a rotation matrix we set V −1
to be the first k columns of U−1([V ∗ V ⊥]). One step remains. Let V ⊥− be equal to V ⊥ except
for the last column, for which the signs are changed. Then V ⊥− is also an orthogonal complement
to V ∗. Thus, let V −1
−
be the first k columns of U−1([V ∗ V ⊥−]). Either V ∗ = V (V −1(V ∗)) or
V ∗ = V (V −1
−
(V ∗)). The candidate for which the equality holds is used to invert V ∗.
C. Gradients of the Objective Function
Let L(D, ξ1, . . . , ξn) be the objective function given in the article. The gradient with respect to
element (a, b), a > b of ξi is
∂L
∂(ξi)ab
= −2
∑
j:(i,j)∈S
tr(ATiab(Mij  (Xij − V (ξi)DiDjV (ξj)T ))V (ξj)DiDj ·
·BTiab(
∂Riab
∂(ξi)ab
)T )− 2
∑
j:(j,i)∈S
tr(ATiab(M
T
ij  (XTij − V (ξi)DiDjV (ξj)T ))V (ξj)·
·DiDjBTiab(
∂Riab
∂(ξi)ab
)T ) + λ3n
−1
v tr(A
T
iabsign(V (ξi)Di)DiB
T
iab(
∂Riab
∂(ξi)ab
)T )+
+λ4n
−1
v
pi∑
j=1
tr(||LijV (ξi)Di||−12 ATiabLTijLijV (ξi)DiDiBTiab(
∂Riab
∂(ξi)ab
)T )
where Aiab, Riab((ξi)ab) and Biab are defined by
AiabRiab((ξi)ab)Biab = R1R2 · · ·RmIpik = V (ξi)
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(see corollary 1), Lij is a row vector with a one at position j and zeros elsewhere and
∂Riab
∂(ξi)ab
=

0a−1 0 0 0 0
0 − sin((ξi)ab) 0 − cos((ξi)ab) 0
0 0 0b−a−1 0 0
0 cos((ξi)ab) 0 − sin((ξi)ab) 0
0 0 0 0 0pi−b
 .
If a 6 b then ∂L/∂(ξi)ab = 0. The gradient with respect to D·i is
∂L
∂Di
= I(−2
∑
j:(i,j)∈S
V (ξi)
T (Mij  (Xij − V (ξi)DiDjV (ξj)T ))V (ξj)Dj−
−2
∑
j:(j,i)∈S
V (ξi)
T (MTij  (XTij − V (ξi)DiDjV (ξj)T ))V (ξj)Dj)+
+λ1sign(D·i) + λ2D·i 
√
(D D)1 + λ3n−1v V (ξi)T sign(V (ξi)Di)+
+λ4n
−1
v
pi∑
j=1
||(V (ξi)Di)j·||−12 (V (ξi)j·  (V (ξi)Di)j·)
where  is elementwise division and 1 is a column vector with each element being 1.
D. Optimization, Algorithmic Details
The most computationally demanding task in MM-PCA is to compute the gradients of the
objective with regard to the matrices ξi. This task has been parallelized across views and uses nv
cores simultaneously.
To improve the convergence rate, the `1 penalties are approximated by a smooth function
based on tangens hyperbolicus as in (Trendafilov and Jolliffe, 2006).
The matrices ξi contain angles in radians, so they are on the scale [−pi, pi]. When selecting
tolerance and stopping criterion for BFGS it is convenient if all variables are on the same scale.
Therefore the data is rescaled so that the biggest singular value, among all the singular values of
all data matrices, is pi2. This results in the variables in D being on approximately the same scale
as ξi.
The penalty parameters λ are rescaled to remove their dependency on the magnitude and size
of the data matrices. In the objective function, each λi is multiplied with a factor c3/2, where
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c = |S|−1∑(i,j)∈S ||Xij ||F , the mean Frobenius norm of the data matrices. The following derives
this factor. Scaling all data by some constant c should lead to scaling all matrix approximations by
the same factor: cViDiDjV Tj = Vi(
√
cDi)(
√
cDj)V
T
j . Thus, if the sum of all penalty terms before
scaling the data was λT f(D·), then after scaling, the sum becomes λT f(
√
cD·) =
√
cλT f(D·).
The last equality is due to penalties being linear in the scale of D·. Multiplying the data
and approximations by c gives the objective
∑
(i,j)∈S ||cXij − cViDiDjV Tj ||2F + λT f(
√
cD·) =
c2
∑
(i,j)∈S ||Xij − ViDiDjV Tj ||2F +
√
cλT f(D·) which has the same minimizing argument as∑
(i,j)∈S ||Xij − ViDiDjV Tj ||2F + c−3/2λT f(D·). Thus, setting λ to c3/2λ removes the dependency
of λ on the scale of the data. This results in the λ parameters being on the same scale regardless
of the scale and size of the data.
D.1 Initialization
As initial values in optimization, we use an approximation of the solution under the assumptions
that all components are globally joint.
We use SVD to set Vi to the loadings of the concatenated matrix consisting of all matrices
(some transposed) with a view i. We find singular values Λij = V Ti XijVj for each matrix. We
factorize Λij into DiDj by greedily choosing signs for each diagonal element in each D· and then
finding the magnitude of the elements with continuous optimization. Finally, the initial values of
ξ· are found using the inverse k-frame operation, V −1, defined above.
E. Integrative Analysis of Gene Expression and Methylation Data for Three
Patient Cohorts
Figures 8-13 show association of the first six components with clinical features. Figure 14 shows
survival plots stratified by cluster assignment.
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E.1 Data Selection, Preprocessing and Normalization
Genomic data from GBM cancer patients from TCGA is publicly available through UCSC cancer
genomics browser (Goldman and others, 2014). The data contains log-transformed RNASeq
counts belonging to 20530 genes for 172 patients. It also contains measurement of methylation at
27578 DNA sites for a partially overlapping group of 288 patients. The measurements are ratios
(so-called β-values) with 0 being unmethylated and 1 being methylated. We quantile normalized
each RNASeq sample, transforming the counts to follow a standard normal distribution based on
the order of genes by count. This removes the dependency of counts on the sequencing depth and
ensures that data follows a normal distribution. For each methylation sample we subtracted the
sample mean from each measurement. Next, we removed sites having median absolute deviation
equal to zero, that is constant across at least half of the patients. This lowered the site count by
2597. We removed half of the genes and half of the sites with lowest variance. We centered genes
and scaled them to have unit variance. We also centered the data for each methylation site. We
divided the patients into three cohorts based on data availability. Cohort 1 contains 96 patients
for which we have gene expression data but not methylation data. Cohort 2 contains 76 patients
for which we have both gene expression and methylation data. Cohort 3 contains 212 patients
for which we have methylation data but no gene expression data. We focus our analysis on four
cellular pathways (mTOR, Ras, MAPK and PI3K-Akt) that are involved in cell proliferation,
survival, migration and angiogenesis (forming of new blood vessels) and are involved in GBM
pathogenesis (Pearson and Regad, 2017). We downloaded gene lists for each pathway from KEGG
(Kanehisa and Goto, 2000). A total of 760 genes were in at least one of the four pathways. Of
these 760 genes 297 remain after the above described gene filtering. Out of the remaining DNA
sites 305 sites are believed to be associated with any of these 297 genes, according to the Infinium
MethylationEPIC v1.0 B4 Manifest file obtained from Illumina. We use all genes and DNA sites
that remain after gene and site filtering to calculate covariance matrices between cohorts 1 and 2
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as well as between cohorts 2 and 3. These two matrices are included in our analysis with the role
of prior information of covariance between the data matrices of gene expressions, and the data
matrices of methylation, respectively. A small proportion (99 elements) of data are missing in
the methylation data. Lastly, we scale each matrix so that the Frobenius norm of its first SVD
component is proportional to the number of observations (rows) in the matrix. To summarize, the
data consists of three patient cohorts of sizes 96, 76 and 212, 297 genes and 305 DNA sites.
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Fig. 8. MM-PCA component 1. Colors in the subtype box-plot are purple for patients with G-CIMP
phenotype, black for non G-CIMP and gray for unknown. Colors in other scatter- and box-plots are as in
Figure 7B: CL: blue, MS: red, NL: green, PN: purple, unknown: gray. Tests for computing p-values are
specified in section 4.2 of the article. The survival plot contrasts survival times of patients with positive
loadings to survival times of patients with negative loadings. The horizontal bar-plot shows the variables
with maximal and minimal loadings.
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Fig. 9. MM-PCA component 2. See caption of Figure 8.
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Fig. 10. MM-PCA component 3. See caption of Figure 8.
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Fig. 11. MM-PCA component 4. See caption of Figure 8.
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Fig. 12. MM-PCA component 5. See caption of Figure 8.
46 J. Kallus and others
Days
0 600 1200 2100 3000 3900
Su
rv
iva
l
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Low
High
p: 0.00083
CL MS NL PN
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Subtype
M
M
−P
C6
l l ll lll l ll lll l ll lll ll lll l llll l l
l
l
l
l
l
l
l
l l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
p: 0.43572
NA Primary Recur. Normal
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Tissue type
M
M
−P
C6
lll l lll ll l l llll l ll
l
l
l
l
l
ll
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
p: 0.53974
NON G−CIMP G−CIMP
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
G−CIMP status
M
M
−P
C6
lll lllll l lll ll
l
l
l
l
l
ll
l
l l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
p: 0.43449
MALE FEMALE
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Sex
M
M
−P
C6
l ll ll ll l l ll lll l llll ll
l
l
l
l
l
l l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
p: < 2.22e−16
GE Both Meth.
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Cohort
M
M
−P
C6
ll lllll lll
l
l
l
l
l
ll
l
ll
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
p: 0.00123
MM−PC6
−1.5 −1.0 −0.5 0.0
Meth.
GE
Max. magnitude variables
TEK
RALBP1
SH2D2A;NTRK1FZD6
MYD88
TGFB2RASSF5
TEK
FZD6
STMN1PAK3
STMN1CCDC22;CACNA1F
PAK3
DUSP9FLNA
IRAK1;MIR718
FOXO4FLNA
IRAK1
EPOCACNG2
WNT16
GRB10LPAR5
FLT3
LPAR4
INS−IGF2;IGF2SYK
RAC2RALGDS
EPONTRK1;INSRR
IL2RA
IL4
CACNG1MAP3K14
LPAR1
TGFB3VWF
l ll l ll lll ll lllll ll lll l llll ll ll lll l l l llll
l
l
l
l
l
ll
l
ll
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
lll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
20 40 60 80
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Age
M
M
−P
C6
p: 0.32103
ll lll lll l ll ll ll lll lll ll lll ll llll lll ll l lll ll ll
l
l
l
l
l
l l
l
l l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l ll
l
l
l
l
l
l
l
l
l
l
l
0.15 0.20 0.25 0.30 0.35 0.40
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
mRNA stemness
M
M
−P
C6
p: 0.88186
ll l l ll ll l ll ll ll lllll l ll ll
l
0.2 0.3 0.4 0.5 0.6
−
0.
3
−
0.
2
−
0.
1
0.
0
0.
1
0.
2
Meth. stemness
M
M
−P
C6
p: 0.612
Fig. 13. MM-PCA component 6. See caption of Figure 8.
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Fig. 14. Survival plots for patients stratified by MM-PCA bi-clustering. The first plot uses cluster assign-
ments based on two components. The second plots uses cluster assignments based on three components.
Colors refer to cluster colors from Figure 7A. P-values are based on Cox regression for patients in the
(dark) blue cluster versus all other patients.
